Abstract
This dose-escalation study of a combination of docetaxel, cisplatin and S-1 investigated the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), recommended dose (RD) and antitumor activity in advanced gastric cancer. Patients received docetaxel (40 mg/m(2)), cisplatin (DIV on day 1) and S-1 (40 mg/m(2) p.o., twice daily, on days 1-14 every 28 days). The starting dose of cisplatin was 60 mg/m(2) (level 1); the dose was escalated to 70 (level 2) and 80 mg/m(2) (level 3) in a stepwise fashion. Fourteen patients were enrolled. The MTD of cisplatin was 80 mg/m(2) (level 3). DLT was grade 3 diarrhea, febrile neutropenia and delayed resumption of treatment. The RD of cisplatin was considered to be 70 mg/m(2) (level 2). DLT was liver dysfunction, occurring in only 1 patient at level 2. The response rate was 69.2% (9/13). For combined treatment with docetaxel, cisplatin and S-1 in patients with advanced gastric cancer, RD were docetaxel 40 mg/m(2), cisplatin 70 mg/m(2) and S-1 80 mg/m(2)/day. This regimen yields a high rate of tumor response and can be administered safely. Phase II studies of this regimen are under way.
Citations
Jul 29, 2011·Cancer Chemotherapy and Pharmacology·Wasaburo KoizumiChikatoshi Katada
Oct 16, 2012·Cancer Chemotherapy and Pharmacology·Yuehong CuiTianshu Liu
Mar 27, 2010·Surgery Today·Masashi FujiiTadatoshi Takayama
Mar 19, 2013·BMC Cancer·Woo Kyun BaeIk-Joo Chung
May 13, 2014·Immunotherapy·Dige Andom Tesfatsion
Oct 19, 2011·Journal of Surgical Oncology·Katsunobu OyamaTetsuo Ohta
Jun 2, 2015·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·J KinoshitaT Ohta
Jun 15, 2016·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Seiji ItoMitsuru Sasako
Apr 25, 2012·Japanese Journal of Clinical Oncology·Hiroshi KatayamaUNKNOWN Stomach Cancer Study Group of the Japan Clinical Oncology Group
Jun 10, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M TaharaA Ohtsu
Jun 23, 2009·Anti-cancer Drugs·Sachio FushidaTetsuo Ohta
Mar 1, 2017·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Hideki UshikuMasahiko Watanabe
Apr 30, 2017·BMC Cancer·Hiroto SaitoTetsuo Ohta
Mar 2, 2017·World Journal of Gastroenterology : WJG·Osamu MaedaYuichi Ando
Dec 4, 2019·Frontiers in Oncology·Fei ZhangZhenning Wang
Nov 20, 2012·Oncology Letters·Yuichiro TadaShin-Etsu Kamata
Apr 11, 2018·Oncotarget·Daisuke FujimotoYasuo Hirono
Feb 29, 2020·Cancer Management and Research·Yuka OheTetsuo Ohta
Mar 4, 2020·International Journal of Clinical Oncology·Kei HosodaNaoki Hiki
Oct 3, 2021·BMC Cancer·Noriyuki HiraharaYoshitsugu Tajima